Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
A phase 2 open-label, randomized, multi-center trial to evaluate the efficacy and safety of
neoadjuvant trastuzumab, pertuzumab and weekly paclitaxel (THP) as compared to neoadjuvant
trastuzumab, pertuzumab, pembrolizumab and weekly paclitaxel (THP-K), or neoadjuvant
trastuzumab, pembrolizumab and weekly paclitaxel (TH-K) in chemo naive patients with invasive
human epidermal growth factor receptor 2 (HER2) positive breast cancer whose primary tumors
are > 2 cm and/or clinically lymph node positive. Treatment will be followed by standard of
care breast surgery and physician's choice adjuvant therapy per standard of care.